Kiromic BioPharma Expands Deltacel-01 Clinical Trials
Kiromic BioPharma, Inc. (OTCQB: KRBP) is excited to announce that the University of Arizona Cancer Center (UACC) is now the fifth site for its Deltacel-01 Phase 1 trial. This study aims to assess the potential of Deltacel™ (KB-GDT-01) in patients suffering from stage 4 metastatic non-small cell lung cancer (NSCLC) who have not had success with standard treatments.
Partnership with the University of Arizona Cancer Center
The UACC is highly regarded as one of the 57 NCI-Designated Comprehensive Cancer Centers in the U.S. Dr. Ricklie Ann Julian, an Assistant Professor of Medicine at UACC, will be leading the site as the Principal Investigator.
Optimism at Kiromic BioPharma
Pietro Bersani, CEO of Kiromic BioPharma, shared his excitement about this collaboration, stating, "We are pleased to partner with UACC. We believe we are in a great position to enroll the upcoming group of patients, and we are hopeful for positive results as we expand the study. UACC has built a strong reputation as a research institution, and we’re eager to work with their respected team."
Patient enrollment is expected to begin soon following the initiation visit at UACC.
Understanding the Deltacel-01 Trial
The Phase 1 clinical trial, called "Phase 1 Trial Evaluating the Safety and Tolerability of Gamma Delta T Cell Infusions in Combination With Low Dose Radiotherapy in Subjects With Stage 4 Metastatic Non-Small Cell Lung Cancer," includes administering two intravenous infusions of Deltacel™ along with four courses of targeted low-dose radiation over a period of 10 days. The primary focus of the trial is on safety, while secondary goals include examining response rates, progression-free survival, overall survival, and disease control rates.
Deltacel™: A Promising Treatment
Deltacel™ (KB-GDT-01) is an innovative gamma delta T-cell therapy currently being investigated in the Deltacel-01 trial for treating stage 4 metastatic NSCLC. This allogeneic product consists of gamma delta T cells derived from donors, demonstrating Kiromic’s dedication to developing a strong GDT platform. Initially aimed at solid tumors, Deltacel™ is significant since NSCLC accounts for a large portion of lung cancer cases and has shown a promising safety and efficacy profile, especially when combined with low-dose radiation.
The Mission of Kiromic BioPharma
Kiromic BioPharma is known as a fully integrated, clinical-stage biotherapeutics company that uses its proprietary DIAMOND® artificial intelligence (AI) engine for target discovery and cell therapy development. This multi-indication allogeneic cell therapy platform is designed to utilize the natural abilities of Gamma Delta T-cells to effectively tackle solid tumors. Based in Houston, Texas, Kiromic is at the forefront of advancements in biotherapeutics.
Conclusion
The recent partnership with the University of Arizona Cancer Center represents a crucial step for Kiromic BioPharma as it works to advance cancer treatment. The Deltacel-01 trial not only offers hope to those affected by NSCLC but also marks a significant leap forward in the broader field of immuno-oncology.
Frequently Asked Questions
What is the Deltacel-01 trial?
The Deltacel-01 trial is a Phase 1 clinical study that evaluates the safety and tolerability of gamma delta T-cell infusions for patients with stage 4 metastatic NSCLC.
Where is the Deltacel-01 trial being conducted?
The trial is taking place at various locations, with the University of Arizona Cancer Center now included among them.
What is the primary goal of the Deltacel-01 trial?
The primary goal of the trial is to assess the safety of the Deltacel™ treatment in patients who have advanced lung cancer.
What is Deltacel™?
Deltacel™ (KB-GDT-01) is an experimental gamma delta T-cell therapy aimed at addressing solid tumors like NSCLC.
Who is leading the trial at the University of Arizona Cancer Center?
Dr. Ricklie Ann Julian, an Assistant Professor of Medicine, is the Principal Investigator leading the Deltacel-01 trial at the UACC.
